News Imfinzi becomes first NHS drug for aggressive lung cancer AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.
News FDA's Makary explains 'overdue' pharma ads crackdown FDA Commissioner Marty Makary has called DTC ads for medicines a "public health crisis" as the industry prepares for a regulatory crackdown.
News RFK Jr expands ACIP ahead of highly anticipated meeting Five members have been added to a controversial CDC vaccines panel ahead of a meeting this week that could have an impact on US immunisation policy.
News Apple Watch hypertension feature cleared by FDA The latest Apple Watch will include a just-approved health feature that will warn users if they show signs of chronic hypertension.
News Lilly lines up Julianne Moore to front brain health campaign Lilly has launched a new awareness campaign in the US, focusing on dementia, and named A-list actress Julianne Moore to front it.
News ICER says GLP-1s 'still have serious affordability issues' Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.